28.57

2.39% -0.706

Alkermes Plc (ALKS)

Overview News Price History Option Chain Financials Why ALKS Down? Discussions Forecast Stock Split

Alkermes Plc stock is traded at $28.57, with a volume of 510.68K. It is down -2.39% in the last 24 hours and down -14.81% over the past month. Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Previous Close:

$29.28

Open:

$29

24h Volume:

510.68K

Relative Volume:

0.27

Market Cap:

$4.76B

Revenue:

$1.51B

Net Income/Loss:

$333.35M

P/E Ratio:

14.65

EPS:

1.95

Net Cash Flow:

$315.22M

1W Performance:

-7.00%

1M Performance:

-14.81%

6M Performance:

-4.54%

1Y Performance:

-18.99%

1-Day Range:

$28.17

$29.18

1-Week Range:

$28.17

$30.49

52-Week Range:

$25.16

$36.32

Alkermes Plc Stock (ALKS) Company Profile

Name

Alkermes Plc

Sector

Healthcare (1111)

Industry

Drug Manufacturers - Specialty & Generic (82)

Phone

00-353-1-772-8000

Address

CONNAUGHT HOUSE, DUBLIN 4

Employee

2,050

Twitter

@alkermes

Next Earnings Date

2024-10-24

Latest SEC Filings

ALKS's Discussions on Twitter

Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALKS Alkermes Plc	28.55	4.88B	1.51B	333.35M	315.22M	1.95
TAK Takeda Pharmaceutical Co Adr	17.70	57.56B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	123.10	53.17B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.27	46.62B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	31.79	38.33B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	481.91	21.48B	3.13B	1.27B	1.12B	26.39

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-25	Initiated	Truist	Buy
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Sep-03-25	Initiated	Wells Fargo	Overweight
Jul-15-25	Initiated	Goldman	Buy
Jun-17-25	Upgrade	UBS	Neutral → Buy
May-28-25	Initiated	Needham	Buy
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform
Mar-04-25	Upgrade	UBS	Sell → Neutral
Feb-11-25	Initiated	Deutsche Bank	Buy
Nov-05-24	Upgrade	Stifel	Hold → Buy
Jun-17-24	Initiated	TD Cowen	Buy
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-20-24	Downgrade	UBS	Neutral → Sell
Nov-20-23	Resumed	JP Morgan	Neutral
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-16-22	Initiated	Piper Sandler	Neutral
Apr-22-22	Resumed	Goldman	Buy
Apr-20-22	Initiated	Goldman	Buy
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight
Dec-01-21	Initiated	Citigroup	Neutral
Oct-07-21	Upgrade	Jefferies	Hold → Buy
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform
Oct-15-20	Upgrade	Mizuho	Neutral → Buy
Jul-30-20	Downgrade	Goldman	Neutral → Sell
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral
Feb-14-20	Reiterated	H.C. Wainwright	Neutral
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-20	Initiated	Mizuho	Neutral
Jan-31-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Sep-05-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-15-19	Upgrade	Goldman	Sell → Neutral
May-31-19	Initiated	H.C. Wainwright	Neutral
May-01-19	Downgrade	Citigroup	Buy → Neutral
Dec-19-18	Downgrade	Goldman	Neutral → Sell
Dec-14-18	Initiated	Wolfe Research	Underperform
Dec-13-18	Downgrade	Credit Suisse	Outperform → Underperform
Nov-05-18	Initiated	Piper Jaffray	Neutral
Aug-07-18	Initiated	Stifel	Hold
Jun-21-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jun-06-18	Initiated	B. Riley FBR, Inc.	Buy
May-16-18	Upgrade	Citigroup	Neutral → Buy
May-11-18	Initiated	BofA/Merrill	Buy

View All

Alkermes Plc Stock (ALKS) Latest News

Mar 04, 2026

Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat

Mar 04, 2026

Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat

Mar 04, 2026

Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat

Mar 04, 2026

Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession - Sleep Review

Mar 03, 2026

Mar 02, 2026

Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen - Yahoo Finance

Mar 02, 2026

Alkermes (NASDAQ: ALKS) insider sells common stock via Form 144 - Stock Titan

Mar 02, 2026

Alkermes (ALKS) Rule 144: Insider sale notice for 6,000 shares, $180K - Stock Titan

Mar 02, 2026

5,000-share exercise and multiple sales reported by Alkermes (ALKS) - Stock Titan

Mar 02, 2026

Alkermes at TD Cowen: Strategic Shift to Sleep Medicine - Investing.com

Mar 02, 2026